Abstract
Reconstituted high density lipoprotein (rHDL) is an excellent and highly biocompatible nanovector mimicking the physical, chemical as well as physiological properties of native high density lipoprotein (HDL), and is originally widely used as the substitute in HDL related studies. Over the past decades, rHDL has increasingly been exploited into vehicles for targeted delivery of numerous drugs, therapeutic genes, etc., and is playing a more and more important role in drug delivery design for regenerative medicine. As such, a systematic review of this promising carrier will be of great importance for subsequent studies. In this article, the term “rHDL-based nanoparticles (rHDLbased NPs)” is employed to refer to rHDL and its modified form. This review highlights four aspects of rHDL-based NPs: current applications in regenerative medicine, preparation methods, conventional evaluation methods, and future trends on co-delivery of drugs for synergic effects.
Keywords: Reconstituted high density lipoprotein-based nanoparticles, drug delivery; regenerative medicine, preparation, evaluation, codelivery.
Current Pharmaceutical Design
Title:Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Volume: 21 Issue: 12
Author(s): Xiaoyi Wang, Jianping Zhou and Wei Wang
Affiliation:
Keywords: Reconstituted high density lipoprotein-based nanoparticles, drug delivery; regenerative medicine, preparation, evaluation, codelivery.
Abstract: Reconstituted high density lipoprotein (rHDL) is an excellent and highly biocompatible nanovector mimicking the physical, chemical as well as physiological properties of native high density lipoprotein (HDL), and is originally widely used as the substitute in HDL related studies. Over the past decades, rHDL has increasingly been exploited into vehicles for targeted delivery of numerous drugs, therapeutic genes, etc., and is playing a more and more important role in drug delivery design for regenerative medicine. As such, a systematic review of this promising carrier will be of great importance for subsequent studies. In this article, the term “rHDL-based nanoparticles (rHDLbased NPs)” is employed to refer to rHDL and its modified form. This review highlights four aspects of rHDL-based NPs: current applications in regenerative medicine, preparation methods, conventional evaluation methods, and future trends on co-delivery of drugs for synergic effects.
Export Options
About this article
Cite this article as:
Wang Xiaoyi, Zhou Jianping and Wang Wei, Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends, Current Pharmaceutical Design 2015; 21 (12) . https://dx.doi.org/10.2174/1381612821666150115130102
DOI https://dx.doi.org/10.2174/1381612821666150115130102 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management
Current Vascular Pharmacology Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function
Mini-Reviews in Medicinal Chemistry Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Cardiovascular & Hematological Disorders-Drug Targets QSAR & Complex Network Study of the HMGR Inhibitors Structural Diversity
Current Drug Metabolism Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Analysis of QTc Interval during Levofloxacin Prescription in Cardiac Patients with Pneumonia
Current Drug Safety Free Radical Scanvenging and Antioxidant Effects of Some Anthraquinone Derivatives
Medicinal Chemistry The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
Current Drug Metabolism Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)